J&J-MERCK PEPCID AC OTC LABEL WILL CLAIM 75% EFFICACY IN PREVENTION OF HEARTBURN; FIRST OTC H2 ANTAGONIST WILL BE AVAILABLE ON RETAIL SHELVES BY SUMMER
Executive Summary
Pepcid AC will carry claims of 70% relief and 75% prevention in an OTC patient labeling insert when it reaches retail shelves this June. FDA approved the Rx-to-OTC switch application from Merck (NDA #20-325) for famotidine in packages of 6, 12 and 18 tabs (10 mg) on April 28, 27 months after the initial submission of the NDA and nine months after an FDA advisory committee asked for statistical reanalysis of data.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth